M. González Cao

Analysis of Copy Number Variations in Solid Tumors Using a Next Generation Sequencing Custom Panel

R. Rosell, F. Pons, M. Molina, 2021, Journal of Molecular Pathology.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

E. Giovannetti, G. Altavilla, R. Rosell, 2017, Drug design, development and therapy.

Survivin expression in sentinel lymph nodes from melanoma patients.

S. Puig, B. Mellado, M. González Cao, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer

R. Rosell, M. Santarpia, J. Menis, 2019, Expert review of clinical pharmacology.

Pharmacological management of relapsed/refractory NSCLC with chemical drugs

R. Rosell, M. Santarpia, N. Karachaliou, 2017, Expert opinion on pharmacotherapy.

Adaptive resistance to targeted therapies in cancer.

R. Rosell, Jia Wei, B. Massuti, 2013, Translational lung cancer research.

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer

G. Altavilla, R. Rosell, M. Santarpia, 2017, Expert opinion on investigational drugs.

Advances in cutaneous melanoma

E. Espinosa, A. Berrocal, S. Martín Algarra, 2012, Clinical and Translational Oncology.

Second-Line Chemotherapy With Irinotecan and Vinorelbine in Stage IIIB and IV Non–Small-Cell Lung Cancer: A Phase II Study

A. Brugarolas, J. Aristu, J. M. Ordóñez, 2002, American journal of clinical oncology.

S-100beta and MIA in advanced melanoma in relation to prognostic factors.

J. Malvehy, S. Puig, R. Molina, 2005, Anticancer research.

Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

Y. Nieto, S. Viteri, J. Aristu, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.